 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 April 1995 | Volume 122 Issue 8 | Pages 561-568
Objective: To examine whether intensive therapy designed to achieve glycemic levels as close to normal as possible prevents or slows the progression of neuropathy when compared with conventional therapy in patients with insulin-dependent diabetes mellitus in the Diabetes Control and Complications Trial.
Design: Multicenter, randomized, controlled clinical trial.
Setting: 29 U.S. and Canadian clinical centers.
Participants: 1441 patients aged 13 to 39 years, of whom 726 had had insulin-dependent diabetes mellitus for 1 to 5 years and had no retinopathy at baseline (primary prevention cohort); 715 had had diabetes for 1 to 15 years and had minimal to moderate nonproliferative retinopathy at baseline (secondary intervention cohort).
Intervention: Intensive therapy with three or more daily insulin injections or continuous subcutaneous insulin infusion guided by four or more glucose tests per day compared with conventional therapy with one or two daily insulin injections.
Results: Intensive therapy reduced the development of confirmed clinical neuropathy (defined as a history or physical examination consistent with clinical neuropathy confirmed by either abnormal nerve conduction or autonomic nervous system testing) by 64% (95% CI, 45% to 76%) in the combined cohorts after 5 years of follow-up (5% of the intensive therapy group compared with 13% of the conventional therapy group). The prevalence of abnormal nerve conduction and abnormal autonomic nervous system function were reduced by 44% (CI, 34% to 53%) and 53% (CI, 24% to 70%), respectively (26% of the intensive treatment group developed abnormal nerve conduction compared with 46% of the conventional treatment group; 4% of the intensive treatment group had abnormal autonomic nervous system function compared with 9% of the conventional treatment group). Finally, nerve conduction velocities generally remained stable with intensive therapy but decreased significantly with conventional therapy.
Conclusion: Intensive diabetes therapy markedly delays or prevents the development of clinically manifest diabetic polyneuropathy as confirmed by objective nerve function testing in patients with insulin-dependent diabetes mellitus.
Author and Article Information
For a complete listing of members of the DCCT Research Group, see: Archives of Ophthalmology. 1995; 113:49-51.
ARTICLE
The Effect of Intensive Diabetes Therapy on the Development and Progression of Neuropathy
Requests for Reprints: The DCCT Research Group, Box NDIC/DCCT, Bethesda, MD 20892.
Grant Support: The DCCT is sponsored by the Division of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institutes of Health, through cooperative agreements and a research contract. Additional support was provided by the National Heart, Lung and Blood Institute; the National Eye Institute; and the National Center for Research Resources.
This article has been cited by other articles:
|
|
 |
|
  A. P. Kellogg, T. D. Wiggin, D. D. Larkin, J. M. Hayes, M. J. Stevens, and R. Pop-Busui Protective Effects of Cyclooxygenase-2 Gene Inactivation Against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fiber Loss in Experimental Diabetes Diabetes, December 1, 2007; 56(12): 2997 - 3005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Ebenezer, J. C. McArthur, D. Thomas, B. Murinson, P. Hauer, M. Polydefkis, and J. W. Griffin Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies Brain, October 1, 2007; 130(10): 2703 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Paterson, B. N. Rutledge, P. A. Cleary, J. M. Lachin, R. S. Crow, and for the Diabetes Control and Complications Trial/E The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Diabetes Care, August 1, 2007; 30(8): 2107 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-c. Wong, J. W Y Chung, and T. K S Wong Effects of treatments for symptoms of painful diabetic neuropathy: systematic review BMJ, July 14, 2007; 335(7610): 87 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Mount Hood 4 Modeling Group Computer Modeling of Diabetes and Its Complications: A report on the Fourth Mount Hood Challenge Meeting Diabetes Care, June 1, 2007; 30(6): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A Little, J. L Edwards, and E. L Feldman Diabetic neuropathies Practical Neurology, April 1, 2007; 7(2): 82 - 92. [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Lewis, M. Legato, and H. Fisch Medical Implications of the Male Biological Clock. JAMA, November 15, 2006; 296(19): 2369 - 2371. [Full Text] [PDF]
|
|
|
|
|
|
K. Thamotharampillai, A. K.F. Chan, B. Bennetts, M. E. Craig, J. Cusumano, M. Silink, P. J. Oates, and K. C. Donaghue Decline in Neurophysiological Function After 7 Years in an Adolescent Diabetic Cohort and the Role of Aldose Reductase Gene Polymorphisms. Diabetes Care, September 1, 2006; 29(9): 2053 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Wilson, M. Ii, K. W. Park, A. Suli, L. K. Sorensen, F. Larrieu-Lahargue, L. D. Urness, W. Suh, J. Asai, G. A.H. Kock, et al. Netrins Promote Developmental and Therapeutic Angiogenesis Science, August 4, 2006; 313(5787): 640 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gilron, C. P. N. Watson, C. M. Cahill, and D. E. Moulin Neuropathic pain: a practical guide for the clinician. Can. Med. Assoc. J., August 1, 2006; 175(3): 265 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Martin, J. Albers, W. H. Herman, P. Cleary, B. Waberski, D. A. Greene, M. J. Stevens, and E. L. Feldman Neuropathy Among the Diabetes Control and Complications Trial Cohort 8 Years After Trial Completion Diabetes Care, February 1, 2006; 29(2): 340 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Bansal, J Kalita, and U K Misra Diabetic neuropathy Postgrad. Med. J., February 1, 2006; 82(964): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Bode, S. Schwartz, H. A. Stubbs, and J. E. Block Glycemic Characteristics in Continuously Monitored Patients With Type 1 and Type 2 Diabetes: Normative values Diabetes Care, October 1, 2005; 28(10): 2361 - 2366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vinik Use of Antiepileptic Drugs in the Treatment of Chronic Painful Diabetic Neuropathy J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4936 - 4945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Corbett Practical Management of Patients With Painful Diabetic Neuropathy The Diabetes Educator, July 1, 2005; 31(4): 523 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Dobrowsky, S. Rouen, and C. Yu Altered Neurotrophism in Diabetic Neuropathy: Spelunking the Caves of Peripheral Nerve J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 485 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steffes, P. Cleary, D. Goldstein, R. Little, H.-M. Wiedmeyer, C. Rohlfing, J. England, J. Bucksa, M. Nowicki, and the DCCT/EDIC Research Group Hemoglobin A1c Measurements over Nearly Two Decades: Sustaining Comparable Values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study Clin. Chem., April 1, 2005; 51(4): 753 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Schroeder, L. E. Chambless, D. Liao, R. J. Prineas, G. W. Evans, W. D. Rosamond, and G. Heiss Diabetes, Glucose, Insulin, and Heart Rate Variability: The Atherosclerosis Risk in Communities (ARIC) study Diabetes Care, March 1, 2005; 28(3): 668 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tesfaye, N. Chaturvedi, S. E.M. Eaton, J. D. Ward, C. Manes, C. Ionescu-Tirgoviste, D. R. Witte, J. H. Fuller, and the EURODIAB Prospective Complications Study Group Vascular Risk Factors and Diabetic Neuropathy N. Engl. J. Med., January 27, 2005; 352(4): 341 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Chang, I. V. Aksenov, A. J.M. Boulton, R. S. Kirsner, and L. Vileikyte Neuropathic Diabetic Foot Ulcers N. Engl. J. Med., October 14, 2004; 351(16): 1694 - 1695. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Castro, A. F. Camargos, E. A. Goulart, and H. S. Junqueira Sonographic Evaluation of Bladder Volume in Diabetic Children and Adolescents Compared With Nondiabetic Subjects J. Ultrasound Med., October 1, 2004; 23(10): 1307 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.M. Boulton, R. A. Malik, J. C. Arezzo, and J. M. Sosenko Diabetic Somatic Neuropathies Diabetes Care, June 1, 2004; 27(6): 1458 - 1486. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Brown, S. J. Bird, S. Watling, H. Kaleta, L. Hayes, S. Eckert, and H. L. Foyt Natural Progression of Diabetic Peripheral Neuropathy in the Zenarestat Study Population Diabetes Care, May 1, 2004; 27(5): 1153 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Saltzman, R. Rashid, A. Hayes, C. Fellner, D. Fitzpatrick, A. Klapach, R. Frantz, and S. L. Hillis 4.5-Gram Monofilament Sensation Beneath Both First Metatarsal Heads Indicates Protective Foot Sensation in Diabetic Patients J. Bone Joint Surg. Am., April 1, 2004; 86(4): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianchi, B. Buyukakilli, M. Brines, C. Savino, G. Cavaletti, N. Oggioni, G. Lauria, M. Borgna, R. Lombardi, B. Cimen, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy PNAS, January 20, 2004; 101(3): 823 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Dworkin, M. Backonja, M. C. Rowbotham, R. R. Allen, C. R. Argoff, G. J. Bennett, M. C. Bushnell, J. T. Farrar, B. S. Galer, J. A. Haythornthwaite, et al. Advances in Neuropathic Pain: Diagnosis, Mechanisms, and Treatment Recommendations Arch Neurol, November 1, 2003; 60(11): 1524 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Team for the Diabetes Control and Complica Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA, October 22, 2003; 290(16): 2159 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Thrainsdottir, R. A. Malik, L. B. Dahlin, P. Wiksell, K. F. Eriksson, I. Rosen, J. Petersson, D. A. Greene, and G. Sundkvist Endoneurial Capillary Abnormalities Presage Deterioration of Glucose Tolerance and Accompany Peripheral Neuropathy in Man Diabetes, October 1, 2003; 52(10): 2615 - 2622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Lenhard and R. E. Maser Sharing the Pain Diabetes Care, May 1, 2003; 26(5): 1606 - 1607. [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Dang and A. J. M. Boulton Changing Perspectives in Diabetic Foot Ulcer Management International Journal of Lower Extremity Wounds, March 1, 2003; 2(1): 4 - 12. [Abstract] [PDF]
|
|
|
|
|
|
K. Ekberg, T. Brismar, B.-L. Johansson, B. Jonsson, P. Lindstrom, and J. Wahren Amelioration of Sensory Nerve Dysfunction by C-Peptide in Patients With Type 1 Diabetes Diabetes, February 1, 2003; 52(2): 536 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Halat and C. E. Dennehy Botanicals and Dietary Supplements in Diabetic Peripheral Neuropathy J Am Board Fam Med, January 1, 2003; 16(1): 47 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pop-Busui, V. Marinescu, C. Van Huysen, F. Li, K. Sullivan, D. A. Greene, D. Larkin, and M. J. Stevens Dissection of Metabolic, Vascular, and Nerve Conduction Interrelationships in Experimental Diabetic Neuropathy by Cyclooxygenase Inhibition and Acetyl-L-Carnitine Administration Diabetes, August 1, 2002; 51(8): 2619 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Writing Team for the Diabetes Control and Comp Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus JAMA, May 15, 2002; 287(19): 2563 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nathan The Impact of Clinical Trials on the Treatment of Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1929 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. M. C.-B. Ferreira, P. U. Huey, B. E. Pulford, D. N. Ishii, and R. H. Eckel Sciatic Nerve Lipoprotein Lipase Is Reduced in Streptozotocin-Induced Diabetes and Corrected by Insulin Endocrinology, April 1, 2002; 143(4): 1213 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Managing Type 2 Diabetes in the Elderly The Diabetes Educator, January 1, 2002; 28(1_suppl): 3 - 11. [PDF]
|
|
|
|
|
|
N. Hotta, T. Toyota, K. Matsuoka, Y. Shigeta, R. Kikkawa, T. Kaneko, A. Takahashi, K. Sugimura, Y. Koike, J. Ishii, et al. Clinical Efficacy of Fidarestat, a Novel Aldose Reductase Inhibitor, for Diabetic Peripheral Neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study Diabetes Care, October 1, 2001; 24(10): 1776 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Verrotti, T. Giuva, G. Morgese, and F. Chiarelli Topical Review : New Trends in the Etiopathogenesis of Diabetic Peripheral Neuropathy J Child Neurol, June 1, 2001; 16(6): 389 - 394. [Abstract] [PDF]
|
|
|
|
|
|
A E Courtney, G V McDonnell, and V H Patterson Human immunoglobulin for diabetic amyotrophy{---}a promising prospect? Postgrad. Med. J., May 1, 2001; 77(907): 326 - 328. [Abstract] [Full Text]
|
|
|
|
|
|
R. D. Hoeldtke, K. D. Bryner, G. G. Horvath, R. W. Phares, L. F. Broy, and G. R. Hobbs Redistribution of Sudomotor Responses Is an Early Sign of Sympathetic Dysfunction in Type 1 Diabetes Diabetes, February 1, 2001; 50(2): 436 - 443. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. THOMAS, Y. SHEN, M. E. MOLITCH, and M. W. STEFFES Rise in Albuminuria and Blood Pressure in Patients Who Progressed to Diabetic Nephropathy in the Diabetes Control and Complications Trial J. Am. Soc. Nephrol., February 1, 2001; 12(2): 333 - 340. [Abstract] [Full Text]
|
|
|
|
|
|
R. D. Hoeldtke, K. D. Bryner, G. R. Hobbs, G. G. Horvath, J. E. Riggs, I. Christie, G. Ganser, S. M. Marcovina, and A. Lernmark Antibodies to Glutamic Acid Decarboxylase and Peripheral Nerve Function in Type 1 Diabetes J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3297 - 3308. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z. Pietrzyk, S. Vogel, G. J. Dietze, and S. F. Rabito Augmented Sympathetic Response to Bradykinin in the Diabetic Heart Before Autonomic Denervation Hypertension, August 1, 2000; 36(2): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Hoeldtke, K. D. Bryner, P. Komanduri, I. Christie, G. Ganser, and G. R. Hobbs Decreased Prorenin Processing Develops before Autonomic Dysfunction in Type 1 Diabetes J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 585 - 589. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Luft Neuropathic pain in diabetic nephropathy—update on analgesic strategies Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2285 - 2288. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Greene, J. C. Arezzo, and M. B. Brown Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy Neurology, August 1, 1999; 53(3): 580 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. M. Molenaar, M. Vermeulen, M. de Visser, and R. de Haan Impact of neurologic signs and symptoms on functional status in peripheral neuropathies Neurology, January 1, 1999; 52(1): 151 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Williams, J. Shenasa, and C. E. Chapman Time Course and Magnitude of Movement-Related Gating of Tactile Detection in Humans. I. Importance of Stimulus Location J Neurophysiol, February 1, 1998; 79(2): 947 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 INTENSIVE INSULIN THERAPY DELAYS DIABETIC NEUROPATHY Journal Watch (General), April 25, 1995; 1995(425): 1 - 1. [Full Text]
|
|
Article
